Patients with peripheral arterial disease in the CHARISMA trial (Q46167781)

20 December 2017

title

Patients with peripheral arterial disease in the CHARISMA trial (English)

1 reference

20 December 2017

0 references

1

1 reference

20 December 2017

Philippe Gabriel Steg

3

1 reference

20 December 2017

Eric J. Topol

4

1 reference

20 December 2017

Deepak L. Bhatt

2

object named as

Deepak L Bhatt

1 reference

20 December 2017

Mark A Creager

5

1 reference

20 December 2017

CHARISMA Investigators

6

1 reference

20 December 2017

publication date

9 January 2009

1 reference

20 December 2017

published in

European Heart Journal

1 reference

20 December 2017

volume

30

1 reference

20 December 2017

issue

2

1 reference

20 December 2017

page(s)

192-201

1 reference

20 December 2017

Critical issues in peripheral arterial disease detection and management: a call to action

cites work

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHN534

Diagnosis and treatment of chronic arterial insufficiency of the lower extremities: a critical review

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHN534

The epidemiology of peripheral arterial disease: importance of identifying the population at risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHN534

ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascul

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHN534

International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHN534

A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHN534

Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHN534

Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHN534

Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHN534

Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHN534

Comparative benefits of clopidogrel and aspirin in high-risk patient populations: lessons from the CAPRIE and CURE studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHN534

Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHN534

Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHN534

Clopidogrel added to aspirin versus aspirin alone in secondary prevention and high-risk primary prevention: rationale and design of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHN534

An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. The GUSTO investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHN534

One-year cardiovascular event rates in outpatients with atherothrombosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHN534

Benefit of clopidogrel over aspirin is amplified in patients with a history of ischemic events

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHN534

The charisma of subgroups and the subgroups of CHARISMA

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHN534

Generalizing the results of clinical trials to actual practice: the example of clopidogrel therapy for the prevention of vascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHN534

21 January 2018

Identifiers

DOI

10.1093/EURHEARTJ/EHN534

1 reference

20 December 2017

1 reference

20 December 2017